Hu, X., Bukhari, S. M., Tymm, C., Adam, K., Lerrer, S., Henick, B. S., Winchester, R. J., & Mor, A. (2024). Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity. Journal for ImmunoTherapy of Cancer, 12(3), e008482. https://doi.org/10.1136/jitc-2023-008482

Zhou, J. J., Chen, L. N., Lehan, T., Herzberg, B., Henick, B. S., Pitman, M., Gallitano, S., & Shu, C. A. (2024). Severe scalp ulcerations and granulomata during treatment with amivantamab. Current Problems in Cancer: Case Reports, 13, 100273. https://doi.org/10.1016/j.cpccr.2023.100273

Mellgard, G., Gilligan, M., Cliff, E. R. S., Bhutani, D., Mohyuddin, G. R., Eisenberger, A., Lentzsch, S., & Chakraborty, R. (2024). Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. HemaSphere, 8(3). Portico. https://doi.org/10.1002/hem3.61

Leibel, L., Mallaiah, S., Ramondetta, L., Bethel, K., Sinton, N., Rao, S., & Cohen, L. (2024). Integrating Yoga in Oncologic Care: Answering the Call to Develop Best Practices. Journal of Integrative and Complementary Medicine, 30(3), 209–215. https://doi.org/10.1089/jicm.2024.0049

Chakraborty, R. (2024). Clinical implications and insights from patient-reported outcome data in KarMMa-3. The Lancet Haematology, 11(3), e175–e176. https://doi.org/10.1016/s2352-3026(24)00028-0

Collins, A., Swann, J. W., Proven, M. A., Patel, C. M., Mitchell, C. A., Kasbekar, M., Dellorusso, P. V., & Passegué, E. (2024). Maternal inflammation regulates fetal emergency myelopoiesis. Cell, 187(6), 1402-1421.e21. https://doi.org/10.1016/j.cell.2024.02.002

Brown, J. R., Ghia, P., Jurczak, W., Kahl, B. S., Lamanna, N., Robak, T., Shadman, M., Tam, C. S., Qiu, L., Paik, J., Salmi, T., Wang, L., Zhang, J., Zhang, M., Cohen, A., Ma, H., & Tedeschi, A. (2024). Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database. Haematologica. https://doi.org/10.3324/haematol.2023.283846

Zorko, N. A., Makovec, A., Elliott, A., Kellen, S., Lozada, J. R., Arafa, A. T., Felices, M., Shackelford, M., Barata, P., Zakharia, Y., Narayan, V., Stein, M. N., Zarrabi, K. K., Patniak, A., Bilen, M. A., Radovich, M., Sledge, G., El-Deiry, W. S., Heath, E. I., … Antonarakis, E. S. (2024). Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-024-00797-0

Jiao, W., Martinez, M., Muntnich, C. B., Zuber, J., Parks, C., Obradovic, A., Tian, G., Wang, Z., Long, K. D., Waffarn, E., Frangaj, K., Jones, R., Gorur, A., Shonts, B., Rogers, K., Lv, G., Velasco, M., Ravella, S., Weiner, J., … Sykes, M. (2024). Dynamic establishment of recipient resident memory T cell repertoire after human intestinal transplantation. EBioMedicine, 101, 105028. https://doi.org/10.1016/j.ebiom.2024.105028

Sabatello, M., Bakken, S., Chung, W. K., Cohn, E., Crew, K. D., Kiryluk, K., Kukafka, R., Weng, C., & Appelbaum, P. S. (2024). Return of polygenic risk scores in research: Stakeholders’ views on the eMERGE-IV study. Human Genetics and Genomics Advances, 5(2), 100281. https://doi.org/10.1016/j.xhgg.2024.100281

Cheng, X., Henick, B. S., & Cheng, K. (2024). Anticancer Therapy Targeting Cancer-Derived Extracellular Vesicles. ACS Nano, 18(9), 6748–6765. https://doi.org/10.1021/acsnano.3c06462

Chen, Y., Markowitz, J. C., Blanco, C., Hershman, D. L., Zhang, J. T., & Hellerstein, D. J. (2024). Geographical distance predicts psychiatric treatment retention for Hispanic women with comorbid major depression and breast cancer. Breast Cancer Research and Treatment, 205(2), 249–256. https://doi.org/10.1007/s10549-024-07250-9

Castellano, C. A., Sun, T., Ravindranathan, D., Hwang, C., Balanchivadze, N., Singh, S. R. K., Griffiths, E. A., Puzanov, I., Ruiz‐Garcia, E., Vilar‐Compte, D., Cárdenas‐Delgado, A. I., McKay, R. R., Nonato, T. K., Ajmera, A., Yu, P. P., Nadkarni, R., O’Connor, T. E., Berg, S., … Ma, K. (2024). The impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study. Cancer, 130(12), 2191–2204. Portico. https://doi.org/10.1002/cncr.35247

Ehrlich, M. I., Hughes, M. S., Labadie, B. W., Siegelin, M. D., D’Ovidio, F., Bijou, R., Lentzsch, S., & Arcasoy, S. M. (2024). Lung Transplantation for Pulmonary AL Amyloidosis. Transplantation Direct, 10(3), e1577. https://doi.org/10.1097/txd.0000000000001577

Lee, A., Runcie, K. D., & Yu, J. B. (2024). The Role of Targeted Radiation Therapy in the Treatment of Renal Cell Carcinoma. Kidney Cancer, 8(1), 45–50. https://doi.org/10.3233/kca-230020

Ferris, J. S., Suzuki, Y., Prest, M. T., Chen, L., Elkin, E. B., Hur, C., Hershman, D. L., & Wright, J. D. (2024). Excess morbidity and mortality associated with underuse of estrogen replacement therapy in premenopausal women who undergo surgical menopause. American Journal of Obstetrics and Gynecology, 230(6), 653.e1-653.e17. https://doi.org/10.1016/j.ajog.2024.02.007

Hasselluhn, M. C., Decker-Farrell, A. R., Vlahos, L., Thomas, D. H., Curiel-Garcia, A., Maurer, H. C., Wasko, U. N., Tomassoni, L., Sastra, S. A., Palermo, C. F., Dalton, T. C., Ma, A., Li, F., Tolosa, E. J., Hibshoosh, H., Fernandez-Zapico, M. E., Muir, A., Califano, A., & Olive, K. P. (2023). Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression. Cancer Discovery, 14(2), 348–361. https://doi.org/10.1158/2159-8290.cd-23-0240

Neelapu, S. S., Chavez, J. C., Sehgal, A. R., Epperla, N., Ulrickson, M., Bachy, E., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Oluwole, O. O., Yakoub-Agha, I., Khanal, R., Rosenblatt, J., Korn, R., Peng, W., Lui, C., … Jacobson, C. A. (2024). Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood, 143(6), 496–506. https://doi.org/10.1182/blood.2023021243

Akahoshi, Y., Spyrou, N., Hoepting, M., Aguayo-Hiraldo, P., Ayuk, F., Chanswangphuwana, C., Choe, H. K., Eder, M., Etra, A. M., Grupp, S. A., Hexner, E. O., Hogan, W. J., Kitko, C. L., Kraus, S., Al Malki, M. M., Merli, P., Qayed, M., Reshef, R., Schechter, T., … Nakamura, R. (2024). Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis. Blood Advances, 8(8), 2047–2057. https://doi.org/10.1182/bloodadvances.2023012091

Spyrou, N., Akahoshi, Y., Kowalyk, S., Morales, G., Beheshti, R., Aguayo-Hiraldo, P., Al Malki, M. M., Ayuk, F., Bader, P., Baez, J., Capellini, A., Choe, H., DeFilipp, Z., Eder, M., Eng, G., Etra, A., Gleich, S., Grupp, S. A., Hexner, E., … Ferrara, J. L. M. (2024). A Day 14 Endpoint for Acute GVHD Clinical Trials. Transplantation and Cellular Therapy, 30(4), 421–432. https://doi.org/10.1016/j.jtct.2024.01.079

Mellgard, G. S., Fojo, T., & Bates, S. E. (2024). Lessons from withdrawn accelerated approvals in oncology. Nature Cancer, 5(2), 211–215. https://doi.org/10.1038/s43018-023-00696-8

He, P., Gambhire, D., Zhou, H., Ma, X., Emura, Y., Laadem, A., Leung, D., Bates, S. E., Fojo, A. T., & Rixe, O. (2024). 76P Utilization of g score in early oncology drug development: Impact on study design and early go/no-go decision. ESMO Open, 9, 102304. https://doi.org/10.1016/j.esmoop.2024.102304

Mahadeo, K. M., Baiocchi, R., Beitinjaneh, A., Chaganti, S., Choquet, S., Dierickx, D., Dinavahi, R., Duan, X., Gamelin, L., Ghobadi, A., Guzman-Becerra, N., Joshi, M., Mehta, A., Navarro, W. H., Nikiforow, S., O’Reilly, R. J., Reshef, R., Ruiz, F., Spindler, T., & Prockop, S. (2024). Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. The Lancet Oncology, 25(3), 376–387. https://doi.org/10.1016/s1470-2045(23)00649-6

Leuzzi, G., Vasciaveo, A., Taglialatela, A., Chen, X., Firestone, T. M., Hickman, A. R., Mao, W., Thakar, T., Vaitsiankova, A., Huang, J.-W., Cuella-Martin, R., Hayward, S. B., Kesner, J. S., Ghasemzadeh, A., Nambiar, T. S., Ho, P., Rialdi, A., Hebrard, M., Li, Y., … Ciccia, A. (2024). SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion. Cell, 187(4), 861-881.e32. https://doi.org/10.1016/j.cell.2024.01.008

Gao, L., Kaushik, D., Van Tine, B. A., Ingham, M. A., Attia, S., Meyer, C. F., Schwartz, G. K., Maliakal, P., Baird, J. D., Ma, J., Barrett, R., D’Silva, D., O’Keefe, K., & Kong, R. (2024). Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma. Clinical and Translational Science, 17(2). Portico. https://doi.org/10.1111/cts.13709

Rogava, M., Aprati, T. J., Chi, W.-Y., Melms, J. C., Hug, C., Davis, S. H., Earlie, E. M., Chung, C., Deshmukh, S. K., Wu, S., Sledge, G., Tang, S., Ho, P., Amin, A. D., Caprio, L., Gurjao, C., Tagore, S., Ngo, B., Lee, M. J., … Izar, B. (2024). Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation. Nature Cancer, 5(3), 433–447. https://doi.org/10.1038/s43018-023-00704-x

Neupane, K., Fortuna, G. G., Dahal, R., Schmidt, T., Fonseca, R., Chakraborty, R., Koehn, K. A., Mohan, M., Mian, H., Costa, L. J., Sborov, D., & Mohyuddin, G. R. (2024). Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer Journal, 14(1). https://doi.org/10.1038/s41408-024-00985-0

Dioun, S., Chen, L., De Meritens, A. B., St. Clair, C. M., Hou, J. Y., Khoury-Collado, F., Pua, T., Hershman, D. L., & Wright, J. D. (2024). Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy. Gynecologic Oncology, 182, 70–74. https://doi.org/10.1016/j.ygyno.2023.12.027

Wolfson, J. A., Grimes, A. C., Nuno, M., Kerber, C. L., Ramakrishnan, S., Beauchemin, M., Dickens, D., Levine, J. M., Roth, M. E., Scialla, M., Woods, W., Vargas, S., Boayue, K. B., Chang, G. J., Stock, W., Hershman, D., Curran, E., Advani, A., O’Dwyer, K., … Parsons, S. K. (2024). Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL. JCO Oncology Practice, 20(4), 491–502. https://doi.org/10.1200/op.23.00328

Straube, J., Bukhari, S., Lerrer, S., Winchester, R. J., Gartshteyn, Y., Henick, B. S., Dragovich, M. A., & Mor, A. (2024). PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis. Arthritis Research & Therapy, 26(1). https://doi.org/10.1186/s13075-023-03259-5

Johansson, H., Guerrieri-Gonzaga, A., Gandini, S., Bertelsen, B.-E., Macis, D., Serrano, D., Mellgren, G., Lazzeroni, M., Thomas, P. S., Crew, K. D., Kumar, N. B., Briata, I. M., Galimberti, V., Viale, G., Vornik, L. A., Aristarco, V., Buttiron Webber, T., Spinaci, S., Brown, P. H., … DeCensi, A. (2024). Alternative dosing regimen of exemestane in a randomized presurgical trial: the role of obesity in biomarker modulation. Npj Breast Cancer, 10(1). https://doi.org/10.1038/s41523-024-00616-8

Kubota, Y., & Viny, A. D. (2024). Germline predisposition for clonal hematopoiesis. Seminars in Hematology, 61(1), 61–67. https://doi.org/10.1053/j.seminhematol.2024.01.007

Wu, F., Jiang, Z., Qian, J., Kobayashi, H., Waterbury, Q. T., White, R. A., Ochiai, Y., Zhi, X., Tu, R., Zheng, B., Shi, Q., Zamechek, L. B., & Wang, T. C. (2024). An optimized protocol for isolation of murine pancreatic single cells with high yield and purity. STAR Protocols, 5(1), 102836. https://doi.org/10.1016/j.xpro.2024.102836

Wang, Y., He, S., Calendo, G., Bui, T., Tian, Y., Lee, C. Y., Zhou, Y., Zhao, X., Abraham, C., Mo, W., Chen, M., Sanders-Braggs, R., Madzo, J., Issa, J.-P., Hexner, E. O., Wiest, D. L., Reshef, R., Xue, H.-H., & Zhang, Y. (2024). Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD. Blood, 143(2), 166–177. https://doi.org/10.1182/blood.2023021126

Kumar, D., Gurrapu, S., Wang, Y., Bae, S.-Y., Pandey, P. R., Chen, H., Mondal, J., Han, H., Wu, C.-J., Karaiskos, S., Yang, F., Sahin, A., Wistuba, I. I., Gao, J., Tripathy, D., Gao, H., Izar, B., & Giancotti, F. G. (2024). LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cells. Nature Cancer, 5(2), 262–282. https://doi.org/10.1038/s43018-023-00695-9

Neo, S. Y., Oliveira, M. M. S., Tong, L., Chen, Y., Chen, Z., Cismas, S., Burduli, N., Malmerfelt, A., Teo, J. K. H., Lam, K.-P., Alici, E., Girnita, L., Wagner, A. K., Westerberg, L. S., & Lundqvist, A. (2024). Natural killer cells drive 4-1BBL positive uveal melanoma towards EMT and metastatic disease. Journal of Experimental & Clinical Cancer Research, 43(1). https://doi.org/10.1186/s13046-023-02917-5

Pakula, H., Omar, M., Carelli, R., Pederzoli, F., Fanelli, G. N., Pannellini, T., Socciarelli, F., Van Emmenis, L., Rodrigues, S., Fidalgo-Ribeiro, C., Nuzzo, P. V., Brady, N. J., Dinalankara, W., Jere, M., Valencia, I., Saladino, C., Stone, J., Unkenholz, C., Garner, R., … Loda, M. (2024). Distinct mesenchymal cell states mediate prostate cancer progression. Nature Communications, 15(1). https://doi.org/10.1038/s41467-023-44210-1

Paudel, B. B., Tan, S.-F., Fox, T. E., Ung, J., Golla, U., Shaw, J. J. P., Dunton, W., Lee, I., Fares, W. A., Patel, S., Sharma, A., Viny, A. D., Barth, B. M., Tallman, M. S., Cabot, M., Garrett-Bakelman, F. E., Levine, R. L., Kester, M., Feith, D. J., … Loughran, T. P. (2024). Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes. Blood Advances, 8(5), 1137–1142. https://doi.org/10.1182/bloodadvances.2023010535

Ehrlich, M. I., Labadie, B. W., Bates, S. E., & Fojo, T. (2024). Mitotane and the myth of 14 mg/L. The Lancet Oncology, 25(1), 12–15. https://doi.org/10.1016/s1470-2045(23)00537-5

Cherng, H.-J. J., & Herrera, A. (2024). Now You “CD20,” Now You Don’t: A Vanishing Act in B-cell Lymphomas After Bispecific Antibody Treatment. The Hematologist, 21(2). https://doi.org/10.1182/hem.v21.2.202425

Zeng, C., Matias‐Gomez, L., Kelly, M., Hershman, D. L., Rosenberg, S., & Pinheiro, L. C. (2024). Psychosocial support among adults living with metastatic breast cancer: Perspectives from providers across four New York‐Presbyterian hospitals. Psycho-Oncology, 33(1). Portico. https://doi.org/10.1002/pon.6296

Pumpalova, Y. S., Ramakrishnan, A., May, M., Pentz, A., Minkowitz, S., Doherty, S., Singh, E., Chen, W. C., Rebbeck, T. R., Neugut, A. I., & Joffe, M. (2023). Biochemical progression free and overall survival among Black men with stage IV prostate cancer in South Africa: Results from a prospective cohort study. Cancer Medicine, 13(1). Portico. https://doi.org/10.1002/cam4.6739

Bardia, A., Pusztai, L., Albain, K., Ciruelos, E. M., Im, S.-A., Hershman, D., Kalinsky, K., Isaacs, C., Loirat, D., Testa, L., Tokunaga, E., Wu, J., Dry, H., Barlow, W., Kozarski, R., Maxwell, M., Harbeck, N., & Sharma, P. (2024). TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241248336

Liu, M. A., Xu, E., & Shu, C. A. (2023). A case study on severe psychiatric symptoms induced by lorlatinib. Psycho-Oncology, 33(1). Portico. https://doi.org/10.1002/pon.6283

Yi, H., Trivedi, M. S., Crew, K. D., Schechter, I., Appelbaum, P., Chung, W. K., Allegrante, J. P., & Kukafka, R. (2024). Understanding Social, Cultural, and Religious Factors Influencing Medical Decision-Making on BRCA1/2 Genetic Testing in the Orthodox Jewish Community. Public Health Genomics, 57–67. Portico. https://doi.org/10.1159/000536391

Shain, J., Michel, A., May, M. S., Qunaj, L., El-Sadr, W., Chung, W. K., Appelbaum, P. S., Jacobson, J. S., Justman, J., & Neugut, A. I. (2023). Cancer genetic mutation prevalence in sub-Saharan Africa: A review of existing data. Seminars in Oncology, 50(6), 123–130. https://doi.org/10.1053/j.seminoncol.2023.12.001

Kinslow, C. J., Siegelin, M. D., Iwamoto, F. M., Gallitto, M., Neugut, A. I., Yu, J. B., Cheng, S. K., & Wang, T. J. C. (2023). MGMT promoter methylation in 1p19q-intact gliomas. Journal of Neuro-Oncology, 166(1), 73–78. https://doi.org/10.1007/s11060-023-04515-z

Altorki, N. K., Walsh, Z. H., Melms, J. C., Port, J. L., Lee, B. E., Nasar, A., Spinelli, C., Caprio, L., Rogava, M., Ho, P., Christos, P. J., Saxena, A., Elemento, O., Bhinder, B., Ager, C., Amin, A. D., Sanfilippo, N. J., Mittal, V., Borczuk, A. C., … McGraw, T. E. (2023). Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-44195-x

Roh, D. J., Murguia-Fuentes, R., Gurel, K., Khasiyev, F., Rahman, S., Bueno, P. P., Kozii, K., Spagnolo-Allende, A. J., Cottarelli, A., Simonetto, M., Ji, R., Guo, J., Spektor, V., Hod, E. A., Burke, D. J., Konofagou, E., Rundek, T., Wright, C. B., Marshall, R. S., … Gutierrez, J. (2024). Relationships of Hematocrit With Chronic Covert and Acute Symptomatic Lacunar Ischemic Lesions. Neurology, 102(2). https://doi.org/10.1212/wnl.0000000000207961

Rudchenko, S., Taylor, S., Milosavic, N., Rudchenko, M., Wedderhoff Tissi, B., Mapara, M. Y., & Stojanovic, M. N. (2023). Amplification of Signal on Cell Surfaces in Molecular Cascades. Cells, 12(24), 2858. https://doi.org/10.3390/cells12242858